Zenas Biopharma Common Etf Performance
| ZBIO Etf | USD 20.88 0.59 2.75% |
The entity maintains a market beta of -1.35, which attests to a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Zenas BioPharma are expected to decrease by larger amounts. On the other hand, during market turmoil, Zenas BioPharma is expected to outperform it.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Zenas BioPharma Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest weak performance, the Etf's forward indicators remain healthy and the recent disarray on Wall Street may also be a sign of long period gains for the ETF investors. ...more
1 | Is Zenas BioPharmas Royalty Deal Quietly Rewriting Its Late-Stage Risk Profile | 12/04/2025 |
2 | Analysts Revenue Estimates For Zenas BioPharma, Inc. Are Surging Higher | 12/24/2025 |
3 | Zenas BioPharma Touts Phase 3 Win, But Stock Crashes | 01/05/2026 |
4 | INVESTOR ALERT Pomerantz Law Firm Investigates Claims On Behalf of InvestorsofZenas BioPharma, Inc. - ZBIO | 01/06/2026 |
5 | Acquisition by Moulder Leon O Jr of 50000 shares of Zenas BioPharma at 16.38 subject to Rule 16b-3 | 01/07/2026 |
6 | Acquisition by Moulder Leon O Jr of 30000 shares of Zenas BioPharma at 16.3 subject to Rule 16b-3 | 01/08/2026 |
7 | Acquisition by Moulder Leon O Jr of 20000 shares of Zenas BioPharma at 16.55 subject to Rule 16b-3 | 01/09/2026 |
8 | Assessing Zenas BioPharma Valuation After Positive INDIGO Phase 3 Trial News | 01/13/2026 |
9 | Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635 | 01/16/2026 |
10 | INVESTOR ALERT Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas BioPharma, Inc. - ZBIO | 01/22/2026 |
| Begin Period Cash Flow | 56.9 M | |
| Total Cashflows From Investing Activities | -30.6 M |
Zenas BioPharma Relative Risk vs. Return Landscape
If you would invest 3,125 in Zenas BioPharma Common on October 31, 2025 and sell it today you would lose (1,037) from holding Zenas BioPharma Common or give up 33.18% of portfolio value over 90 days. Zenas BioPharma Common is currently does not generate positive expected returns and assumes 9.3505% risk (volatility on return distribution) over the 90 days horizon. In different words, 84% of etfs are less volatile than Zenas, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Zenas BioPharma Target Price Odds to finish over Current Price
The tendency of Zenas Etf price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 20.88 | 90 days | 20.88 | about 89.72 |
Based on a normal probability distribution, the odds of Zenas BioPharma to move above the current price in 90 days from now is about 89.72 (This Zenas BioPharma Common probability density function shows the probability of Zenas Etf to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days Zenas BioPharma Common has a beta of -1.35. This usually means as returns on its benchmark rise, returns on holding Zenas BioPharma Common are expected to decrease by similarly larger amounts. On the other hand, during market turmoils, Zenas BioPharma is expected to outperform its benchmark. Additionally Zenas BioPharma Common has an alpha of 0.4457, implying that it can generate a 0.45 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Zenas BioPharma Price Density |
| Price |
Predictive Modules for Zenas BioPharma
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Zenas BioPharma Common. Regardless of method or technology, however, to accurately forecast the etf market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the etf market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Zenas BioPharma Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Zenas BioPharma is not an exception. The market had few large corrections towards the Zenas BioPharma's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Zenas BioPharma Common, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Zenas BioPharma within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.45 | |
β | Beta against Dow Jones | -1.35 | |
σ | Overall volatility | 8.27 | |
Ir | Information ratio | 0.03 |
Zenas BioPharma Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Zenas BioPharma for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Zenas BioPharma Common can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Zenas BioPharma generated a negative expected return over the last 90 days | |
| Zenas BioPharma has high historical volatility and very poor performance | |
| Zenas BioPharma has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 5 M. Net Loss for the year was (156.99 M) with loss before overhead, payroll, taxes, and interest of (146.5 M). | |
| The fund created three year return of -33.0% | |
| About 66.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from prnewswire.com: INVESTOR ALERT Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas BioPharma, Inc. - ZBIO | |
| Zenas BioPharma Common keeps most of the net assets in exotic instruments. |
Zenas BioPharma Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Zenas Etf often depends not only on the future outlook of the current and potential Zenas BioPharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Zenas BioPharma's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 41.8 M | |
| Cash And Short Term Investments | 350.8 M |
Zenas BioPharma Fundamentals Growth
Zenas Etf prices reflect investors' perceptions of the future prospects and financial health of Zenas BioPharma, and Zenas BioPharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Zenas Etf performance.
| Return On Equity | -0.68 | ||||
| Return On Asset | -0.34 | ||||
| Operating Margin | (13.05) % | ||||
| Current Valuation | 862.41 M | ||||
| Shares Outstanding | 53.68 M | ||||
| Price To Book | 5.87 X | ||||
| Price To Sales | 76.83 X | ||||
| Revenue | 5 M | ||||
| EBITDA | (163.75 M) | ||||
| Total Debt | 1 M | ||||
| Book Value Per Share | 4.65 X | ||||
| Cash Flow From Operations | (119.67 M) | ||||
| Earnings Per Share | 13.67 X | ||||
| Total Asset | 369.97 M | ||||
| Retained Earnings | (387.39 M) | ||||
About Zenas BioPharma Performance
By examining Zenas BioPharma's fundamental ratios, stakeholders can obtain critical insights into Zenas BioPharma's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Zenas BioPharma is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
The investment seeks daily investment results, before fees and expenses, that correspond to three times the inverse of the daily performance of the NASDAQ Biotechnology Index. ProShares UltraPro is traded on NGM Exchange in the United States.| Zenas BioPharma generated a negative expected return over the last 90 days | |
| Zenas BioPharma has high historical volatility and very poor performance | |
| Zenas BioPharma has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 5 M. Net Loss for the year was (156.99 M) with loss before overhead, payroll, taxes, and interest of (146.5 M). | |
| The fund created three year return of -33.0% | |
| About 66.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from prnewswire.com: INVESTOR ALERT Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas BioPharma, Inc. - ZBIO | |
| Zenas BioPharma Common keeps most of the net assets in exotic instruments. |
Other Information on Investing in Zenas Etf
Zenas BioPharma financial ratios help investors to determine whether Zenas Etf is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Zenas with respect to the benefits of owning Zenas BioPharma security.